See you next week on ICAPA congress in Kyoto

Deep dive into macrovascular APS：new findings and new evidence

our new research on SLE-PAH has been accepted and published on <the innovation>

What percentage of APS patients experience delayed diagnosis? The result is shocking: over 60%. Based on a Chinese prospective cohort study. published in Clinical Rheumatology

Risk stratification and subgroup analysis of systemic lupus erythematosus patients with pregnancy: based on a 13‑year multi-center cohort study

These images are typical cases from my clinical practice，APLs+ livedo reticularis, hepatic infarction, dementia, chorea, and retinal vasculitis. their manifestations cannot be fully explained by thrombotic events alone-APS is far more than you think！

Having presentations in three different international congresses, all in Japan, was such an amazing experience: APLAR, 1st International congress on molecular targeted treatments, and ICAPA2025-International congress on antiphospholipid antibodies. Great topics and discussions.

#Lupus nephritis affects 25–60% of patients with #SLE and remains a substantial cause of morbidity and mortality. Honoured to co-author a review article on #Lupus nephritis published in #Nature Reviews Disease Primers. Nature Reviews Disease Primers Read more: rdcu.be/eH6A4

the new SLE guideline was released and how will we treat SLE in next 5 years？

Wish you and your family a happy Mid-Autumn Festival ！

morning，Chicago

We're learning how to control our immune system and cure some patients with autoimmune diseases, like lupus and multiple sclerosis. After CAR T (vs protein on B cell surface, CD19 or CD20) the new B cells are rebooted, no longer self attack

The development and validation of a EULAR disease activity score in #Antiphospholipid syndrome. Honored to chair this EULAR Task Force with the contribution of an international group of #APS experts/Collaborators, patients with APS, and HPRs. sciencedirect.com/science/articl…

🦴🔥 HOPE Trial – Prednisolone in Hand Osteoarthritis 🧩 Background 🖐️ Hand OA → high pain + disability ❌ Limited effective therapies 🔥 Synovial inflammation plays a key role 🎯 Aim: Test short-term oral prednisolone in inflammatory hand OA flare 🧪 Methods 🔬 Design:

The editors announce the launch of NEJM Clinician (follow 👉 NEJM Clinician), a new digital publication for clinicians, by clinicians. Read the editorial: nej.md/4roG5vK